|
| |
Prosidion Ltd(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Phase IIa clinical studies and PSN010, a glucokinase activator, has recently entered Phase I clinical trials. (OSI) Prosidion owns or has licensing rights to a portfolio of DP-IV medical use patents with claims covering DP-IV as a target for anti-diabetes therapy and the use of combinations of DP-IV inhibitors with other anti-diabetes drugs such as metformin. A number of non-exclusive licenses to the patent estate have been granted to major pharmaceutical companies. (OSI) Prosidion operates through OSI's wholly-owned subsidiary, Prosidion Limited, in Oxford, UK
| Contact Details: |
| Watlington Road |
| Oxford |
| Oxfordshire |
| OX4 6LT |
| United Kingdom |
| Tel: | 44 (0)1865 782600 |
| Fax: | 44 (0)1865 782601 |
| Email: | Info@Prosidion.com |
| WWW: | www.prosidion.com/

|
|
Loading...
|
Recent Publications by Prosidion Ltd: |  |
5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
The noradrenaline (NA) and serotonin reuptake inhibitor, sibutramine,... | 6th June, 2009
| Prosidion Research,
| Obesity (Silver Spring). 2009 Mar;17(3):467-73. Epub 2008 Dec 11.
DOI Direct Link |
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
Allosteric activators of the glucose-sensing enzyme glucokinase (GK) are... | 30th August, 2008
| OSI) Prosidion, Windrush Court, Watlington Road, Oxford OX4 6LT, United
| J Med Chem. 2008 Jul 24;51(14):4340-5. Epub 2008 Jun 28.
DOI Direct Link |
GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
GPR119 is a G protein-coupled receptor expressed predominantly in the... | 29th April, 2008
| (OSI) Prosidion,
| Br J Pharmacol. 2008 Mar;153 Suppl 1:S76-81. Epub 2007 Nov 26.
DOI Direct Link |
PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.
BACKGROUND AND PURPOSE: Rimonabant (Acomplia, SR141716A), a cannabinoid... | 26th February, 2008
| Prosidion Limited, Windrush Court, Oxford, UK.
| Br J Pharmacol. 2007 Nov;152(5):805-14. Epub 2007 Jun 25.
DOI Direct Link |
Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.
AIMS/HYPOTHESIS: We evaluated the insulinotropic and antihyperglycaemic... | 18th October, 2007
| (OSI)Prosidion, Windrush Court, Watlington Road, Oxford, UK.
| Diabetologia. 2007 Jun;50(6):1277-87. Epub 2007 Apr 6.
DOI Direct Link |
→View more Prosidion Ltd research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 6120 times since April 2007, the link to the organisation's website has been followed 1443 times Recent Search Terms used to find this page: prosidion | prosidion | prosidion | OSI Prosidion | OSI Prosidion | prosidion | prosidion | osi and prosidion | prosidion | prosidion ltd | . Search for more companies in Oxford Search for more companies in Oxfordshire This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Prosidion Ltd |